Skip to main content

Advertisement

SpringerLink
Log in

Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients

  • Original Paper
  • Published:
Angiogenesis Aims and scope Submit manuscript

Abstract

Vascular endothelial growth inhibitor (VEGI) is a novel anti-angiogenic cytokine that belongs to the tumour necrosis factor (TNF) superfamily. Very little is known about the significance of VEGI in cancer. Our study analysed VEGI expression in relation to breast cancer patient clinical parameters. The VEGI expression profile was assessed qualitatively (RT-PCR), quantitatively (real-time Quantitative-PCR), and immuno-histochemically (IHC), in a panel of 24 human normal and cancer cell lines and in a cohort of 151 mammary tissue samples (n = 33 normal breast tissue; n = 118 breast cancer tissue) with a 6-year median follow-up. Patients who had died of breast cancer or had local recurrence of the disease expressed significantly lower levels of VEGI in comparison to the elevated levels in the disease free patients. High levels of VEGI were associated with an increased chance of patient survival. Importantly, patients with breast tumours expressing reduced levels of VEGI had a poorer prognosis than those patients expressing high levels of VEGI. However, no significant correlations were observed between VEGI expression and tumour grade, TNM classification, or nodal involvement. In conclusion, VEGI is aberrantly expressed in human breast cancer tissues. VEGI displays prognostic relevance as breast cancer patients with an overall poor prognosis express significantly lower levels of VEGI compared to those with a favourable prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Althuis MD, Dozier JM, Anderson WF et al (2005) Global trends in breast cancer incidence and mortality 1973–1997. Int J Epidemiol 34:405–412

    Article  PubMed  Google Scholar 

  2. Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16:481–488

    Article  PubMed  CAS  Google Scholar 

  3. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4–6

    Article  PubMed  CAS  Google Scholar 

  4. Blood CH, Zetter BR (1990) Tumour interactions with the vasculature: angiogenesis and tumour metastasis. Biochim Biophys Acta 1032:89–118

    PubMed  CAS  Google Scholar 

  5. Guidi AJ, Berry DA, Broadwater G et al (2000) Association of angiogenesis in lymph node metastases with outcome of breast cancer. J Natl Cancer Inst 92:486–492

    Article  PubMed  CAS  Google Scholar 

  6. Li J, Song ST, Jiang ZF et al (2003) Significance of microvascular density and vascular endothelial growth factor in breast cancer. Zhonghua Zhong Liu Za Zhi 25:145–148

    PubMed  CAS  Google Scholar 

  7. Gasparini G (1996) Clinical significance of the determination of angiogenesis in human breast cancer: update of the biological background and overview of the Vincenza studies. Eur J Cancer 32:2485–2493

    Article  Google Scholar 

  8. Weidner N, Folkman J, Pozza F et al (1992) Tumour angiogenesis: a new significant and independent prognostic indicator in early stage breast carcinoma. J Natl Cancer Inst 84:1875–1887

    Article  PubMed  CAS  Google Scholar 

  9. Bosari S, Lee AK, DeLellis RA et al (1992) Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 23:755–761

    Article  PubMed  CAS  Google Scholar 

  10. Toi M, Kashitani J, Tominaga T (1991) Tumour angiogenesis is an independent prognostic indicator in primary breast carcinoma. N Engl J Med 324:1–8

    Article  Google Scholar 

  11. Horak ER, Leek R, Klenk N et al (1992) Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340:1120–1124

    Article  PubMed  CAS  Google Scholar 

  12. Tsutsui S, Kume M, Era S (2003) Prognostic value of microvessel density in invasive ductal carcinoma of the breast. Breast Cancer 10:312–319

    Article  PubMed  Google Scholar 

  13. Toi M, Inada K, Suzuki H et al (1995) Tumour angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat 36:193–204

    Article  PubMed  CAS  Google Scholar 

  14. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353–364

    Article  PubMed  CAS  Google Scholar 

  15. Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2:795–803

    Article  PubMed  CAS  Google Scholar 

  16. Dvorak HF (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumour angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20:4368–4380

    Article  PubMed  CAS  Google Scholar 

  17. Maeda K, Chung YS, Ogawa Y et al (1996) Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 77:858–863

    Article  PubMed  CAS  Google Scholar 

  18. Zhang HT, Craft P, Scott PA et al (1995) Enhancement of tumour growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cell. J Natl Cancer Inst 87:213–219

    Article  PubMed  CAS  Google Scholar 

  19. Linderholm B, Tavelin B, Grankvist K et al (1998) Vascular endothelial growth factor is of high prognostic value in node negative breast carcinoma. J Clin Oncol 16:3121–3128

    PubMed  CAS  Google Scholar 

  20. Gasparani G, Toi M, Gion M (1997) Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89:139–147

    Article  Google Scholar 

  21. Zhai Y, Yu J, Iruela-Arispe L et al (1999) Inhibition of angiogenesis and breast cancer xenograft tumour growth by VEGI, a novel cytokine of the TNF superfamily. Int J Cancer 82:131–136

    Article  PubMed  CAS  Google Scholar 

  22. Shakibaei M, Schulze-Tanzil G, Takada Y et al (2005) Redox regulation of apoptosis by members of the TNF superfamily. Antioxid Redox Signal 7:482–496

    Article  PubMed  CAS  Google Scholar 

  23. Havell EA, Fiers W, North RJ (1990) The anti-tumour function of tumour necrosis factor (TNF). J Exp Med 167:1067–1085

    Article  Google Scholar 

  24. Asher AL, Mule JJ, Reichert CM et al (1987) Studies on the anti-tumour efficacy of systemically administered recombinant tumour necrosis factor against several murine tumors in vivo. J Immunol 138:963–974

    PubMed  CAS  Google Scholar 

  25. Zhai Y, Ni J, Jiang G et al (1999) VEGI, a novel cytokine of the tumour necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J 13:181–189

    PubMed  CAS  Google Scholar 

  26. Migone TS, Zhang J, Luo X et al (2002) TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 16:479–492

    Article  PubMed  CAS  Google Scholar 

  27. Yang CR, Hsieh SL, Teng CM et al (2004) Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumour necrosis factor superfamily and exhibiting angiostatic action. Cancer Res 64:1122–1129

    Article  PubMed  CAS  Google Scholar 

  28. Parr C, Watkins G, Mansel RE et al (2004) The hepatocyte growth factor regulatory factors and human breast cancer. Clin Cancer Res 10:202–211

    Article  PubMed  CAS  Google Scholar 

  29. Jiang WG, Douglas-Jones A, Mansel RE (2003) Level of expression of PPAR-gamma and its co-activator (PPAR-GCA) in human breast cancer. Int J Cancer 106:752–757

    Article  PubMed  CAS  Google Scholar 

  30. Parr C, Jiang WG (2001) Expression of hepatocyte growth factor/scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells. Int J Oncol 19:857–863

    PubMed  CAS  Google Scholar 

  31. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27–31

    Article  PubMed  CAS  Google Scholar 

  32. Peter C, Rakesh KJ (2000) Angiogenesis in cancer and other diseases. Nature 407:249–257

    Article  Google Scholar 

  33. Uzzan B, Nicolas P, Cucherat M et al (2004) Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 64:2941–2955

    Article  PubMed  CAS  Google Scholar 

  34. Carmeliet P (2000) Mechanisms of angiogenesis and arteriogenesis. Nat Med 6:389–395

    Article  PubMed  CAS  Google Scholar 

  35. Yu J, Tian S, Metheny-Barlow L et al (2001) Modulation of endothelial cell growth arrest and apoptosis by vascular endothelial growth inhibitor. Circ Res 89:1161–1167

    Article  PubMed  CAS  Google Scholar 

  36. Hou W, Medynski D, Wu S et al (2005) VEGI-192, a new isoform of TNFSF15, specifically eliminates tumour vascular endothelial cells and suppresses tumour growth. Clin Cancer Res 11:5595–5602

    Article  PubMed  CAS  Google Scholar 

  37. Chew LJ, Pan H, Yu J et al (2002) A novel secreted splice variant of vascular endothelial cell growth inhibitor. FASEB J 16:742–744

    PubMed  CAS  Google Scholar 

  38. Lehmann W, Edgar CM, Wang K et al (2005) Tumour necrosis factor alpha (TNF-alpha) coordinately regulates the expression of specific matrix metalloproteinases (MMPS) and angiogenic factors during fracture healing. Bone 36:300–310

    Article  PubMed  CAS  Google Scholar 

  39. Xiao Q, Hsu CY, Chen H et al (2005) Characterization of cis-regulatory elements of the vascular endothelial growth inhibitor gene promoter. Biochem J 388:913–920

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors wish to thank the Breast Cancer Campaign and Cancer Research Wales (CRW) for supporting this work.

Author information

Authors and Affiliations

  1. Department of Surgery, Wales College of Medicine, Metastasis and Angiogenesis Research Group, Cardiff University, Heath Park, Cardiff, CF14-4XN, UK

    Christian Parr, Chun H. Gan, Gareth Watkins & Wen G. Jiang

Authors
  1. Christian Parr
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chun H. Gan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gareth Watkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wen G. Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Parr.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Parr, C., Gan, C.H., Watkins, G. et al. Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients. Angiogenesis 9, 73–81 (2006). https://doi.org/10.1007/s10456-006-9033-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10456-006-9033-1

Keywords

Search

Navigation